KIPO Shares ADC Patent Big Data Analysis Results... Laying the Foundation for New Drug Development

The Korean Intellectual Property Office (KIPO) is supporting new drug development by releasing the results of big data analysis on ADC (Antibody Drug Conjugate) patents.

ADC is a next-generation anticancer agent that connects antibodies and drugs with a linker, enhancing drug efficacy while compensating for the drawbacks and side effects of conventional anticancer drugs. The global market research firm Research and Markets has predicted that the global ADC market will grow from $5.9 billion in 2022 to $13 billion in 2026.

Provided by the Korean Intellectual Property Office

KIPO announced on the 28th that it will hold the ‘ADC Patent Analysis Results Presentation for New Drug Development’ with the National New Drug Development Industry Group at the Seoul Garden Hotel on the 14th of next month.

ADC is a type of antibody-drug conjugate in which a drug is linked to an antibody that binds to a specific target antigen via a linker. Anticancer drugs incorporating this technology travel through the bloodstream and, upon encountering target cancer cells, penetrate the cells to release the drug, thereby killing the cancer cells.

The presentation was planned to provide promising technologies and key core patents derived from big data analysis of ADC-related patents to domestic pharmaceutical and bio developers.

At this event, KIPO plans to discuss ways to utilize the ADC patent analysis results for research and development (R&D), providing customized information suited to the domestic pharmaceutical and bio R&D field, thereby laying the groundwork to enhance global competitiveness.

To attend the presentation, pre-registration or on-site registration is required. Pre-registration can be done from the 28th by referring to the notice on the National New Drug Development Project Group’s website.

Mok Seong-ho, Director of the Industrial Property Policy Bureau at KIPO, emphasized, “Patent big data provides market-oriented technical information that can offer objective evidence necessary for predicting future industries and technologies, serving as an objective criterion in the R&D planning stage. Especially in the pharmaceutical and bio fields, where concerns about patent disputes are relatively high, patent analysis at the R&D planning stage is very important.”

Muk Hyun-sang, Director of the National New Drug Development Project Group, said, “With the advent of a major bio transformation era, securing core technologies for new substance drugs that overcome the limitations of existing treatments has become crucial. We hope this presentation will serve as a game changer in the anticancer drug market and act as a stepping stone for practical ‘ADC new drug development.’”

This content was produced with the assistance of AI translation services.